title: Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
abstract: This study evaluates the in vitro sensitivities of 42 ovarian cancer specimens to the new anticancer agent Paclitaxel (taxol, Tx), cisplatin (DDP), and the combination Tx-DDP with the adenosine triphosphate cell viability assay (ATP-CVA). In vitro response is defined by > or = 50% ATP decrease compared to untreated controls 6-7 days after drug treatment with 20% of the peak plasma concentration (PPC). Response rates were 12% to Tx, 19% to DDP, and 27% to Tx + DDP. The mean IC50's of Tx, DDP, and the combination Tx-DDP were (2.6x, 1.0x, and 0.38x PPC, respectively). The mean inhibition of cell viability was significantly greater with drug combinations compared to single drugs. In 7/11 tumors synergistic effects and in 2/11 additive effects were found between Tx and DDP. We conclude that based on ATP-CVA in vitro results, Tx-DDP shows significantly better activity compared to each of the single drugs in ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, University of Miami School of Medicine, Florida 33101.
authors.forename: M
authors.initials: M
authors.lastname: Untch
authors.forename: B U
authors.initials: BU
authors.lastname: Sevin
authors.forename: J P
authors.initials: JP
authors.lastname: Perras
authors.forename: R
authors.initials: R
authors.lastname: Angioli
authors.forename: A
authors.initials: A
authors.lastname: Untch
authors.forename: R D
authors.initials: RD
authors.lastname: Hightower
authors.forename: O
authors.initials: O
authors.lastname: Koechli
authors.forename: H E
authors.initials: HE
authors.lastname: Averette
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis* / Q000037:antagonists & inhibitors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000255:Adenosine Triphosphate; D017239:Paclitaxel; D002945:Cisplatin